Oryzon Genomics–JMP Securities: investor conference, 201706 supply service Oryzon at JMP Securities 2017 Life Sciences Conference NY

	Period	2017-06-20
	Region	New York, NY
	Country	United States (USA)
	Partner, 1st	Oryzon Genomics S.A. (Madrid Stock Exchange: ORY)
	Group	Oryzon Genomics (Group)
	Partner, 2nd	JMP Securities LLC
	Today	Citizens JMP Securities LLC
	Product	JMP Securities Life Sciences Conference 2017 New York
	Product 2	LSD1 inhibitor (Lysine Specific Demethylase-1 inhibitor)
	Person	Buesa, Carlos (Oryzon Genomics SA 201404 CEO + Co-Founder)
	Person 2	Kelman, Maria (Pieris 201805 Investor Relations before Trout Group 201705)

Oryzon Genomics S.A.. (5/31/17). "Press Release: Oryzon Genomics to Participate in a Panel at the JMP Securities Life Sciences Conference and Present at the Jefferies 2017 Global Health Conference". Barcelona & Cambridge, MA.

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that:

> Dr. Buesa will present at the Jefferies 2017 Global Healthcare Conference, June 9th 2017 at 12:30pm Eastern Time at The Grand Hyatt Hotel in New York;

> Dr. Buesa will participate in a panel discussion titled: “Epigenetics and Transcriptional Control - Regulating the Regulators” at The JMP Securities Life Sciences Conference, June 20th 2017 at 11 am Eastern Time at The St. Regis New York;

In addition, any investor attending the conferences that wish to meet with Oryzon’s management can also contact our IR firm the Trout Group (mkelman@troutgroup.com), and our IR Director Anna Baran-Djokovic at abaran@oryzon.com.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon’s LSD1 program is currently covered by + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forwardlooking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A, have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This
press release is not an offer of securities for sale in the United States. The Company’s securities may not be offered
or sold in the United States absent registration or an exemption from registration. Any public offering of the Company’s securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

US Contact:
The Trout Group
Maria Kelman
+1 646 378 2932
mkelman@troutgroup.com

Spain:
ATREVIA
Patricia Cobo/Luis Rejano
+34 91 564 07 25
pcobo@atrevia.com
lrejano@atrevia.com

The Company:
Anna K Baran
IR Director
+44 (0) 752 1083 006
abaran@oryzon.com